Kost Gerald J
Fulbright Scholar 2020-2022, ASEAN Program, Point-of-Care Testing Center for Teaching and Research (POCT•CTR), Pathology and Laboratory Medicine, School of Medicine, University of California, Davis, CA 95616, USA.
Diagnostics (Basel). 2022 May 12;12(5):1216. doi: 10.3390/diagnostics12051216.
This research uses mathematically derived visual logistics to interpret COVID-19 molecular and rapid antigen test (RAgT) performance, determine prevalence boundaries where risk exceeds expectations, and evaluate benefits of recursive testing along home, community, and emergency spatial care paths. Mathematica and open access software helped graph relationships, compare performance patterns, and perform recursive computations. Tiered sensitivity/specificity comprise: (T1) 90%/95%; (T2) 95%/97.5%; and (T3) 100%/≥99%, respectively. In emergency medicine, median RAgT performance peaks at 13.2% prevalence, then falls below T1, generating risky prevalence boundaries. RAgTs in pediatric ERs/EDs parallel this pattern with asymptomatic worse than symptomatic performance. In communities, RAgTs display large uncertainty with median prevalence boundary of 14.8% for 1/20 missed diagnoses, and at prevalence > 33.3−36.9% risk 10% false omissions for symptomatic subjects. Recursive testing improves home RAgT performance. Home molecular tests elevate performance above T1 but lack adequate validation. Widespread RAgT availability encourages self-testing. Asymptomatic RAgT and PCR-based saliva testing present the highest chance of missed diagnoses. Home testing twice, once just before mingling, and molecular-based self-testing, help avoid false omissions. Community and ER/ED RAgTs can identify contagiousness in low prevalence. Real-world trials of performance, cost-effectiveness, and public health impact could identify home molecular diagnostics as an optimal diagnostic portal.
本研究使用数学推导的视觉逻辑来解释新冠病毒分子检测和快速抗原检测(RAgT)的性能,确定风险超过预期的流行率界限,并评估在家庭、社区和紧急空间护理路径中进行递归检测的益处。Mathematica软件和开源软件有助于绘制关系图、比较性能模式并进行递归计算。分级灵敏度/特异性分别包括:(T1)90%/95%;(T2)95%/97.5%;以及(T3)100%/≥99%。在急诊医学中,RAgT的性能中位数在流行率为13.2%时达到峰值,然后降至T1以下,产生有风险的流行率界限。儿科急诊室/急诊科的RAgT呈现出类似模式,无症状者的检测性能比有症状者更差。在社区中,RAgT显示出很大的不确定性,对于1/20的漏诊,中位数流行率界限为14.8%,当流行率>33.3−36.9%时,有症状受试者的漏诊风险为10%。递归检测可提高家庭RAgT的性能。家用分子检测可将性能提升至T1以上,但缺乏充分验证。广泛可得的RAgT鼓励自我检测。无症状RAgT检测和基于PCR的唾液检测漏诊的可能性最高。在家进行两次检测,一次在社交活动前,以及基于分子的自我检测,有助于避免漏诊。社区和急诊室/急诊科的RAgT可在低流行率情况下识别传染性。对性能、成本效益和公共卫生影响进行的真实世界试验可能会确定家用分子诊断为最佳诊断途径。